Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, switch maintenance study of MRx0518 and Avelumab in patients with
unresectable locally advanced or metastatic urothelial carcinoma (UC) whose disease did not
progress after 4 to 6 cycles of first-line platinum-containing chemotherapy and who have
residual measurable disease according to Response Evaluation Criteria in Solid Tumors version
1.1 (RECIST v1.1). Up to 30 patients will be enrolled.
Patients enrolled in this study will be treated with IV Avelumab every 2 weeks and MRx0518
daily during the treatment period. Patients will receive the study treatment until disease
progression (PD), patient withdrawal, or unacceptable toxicity.